Figure 8. The OXPHOS‐mediated lipogenic reprogramming is prevented by edaravone.

The schematic illustrates the effect of in vivo edaravone administration in Skm from Low_OXPHOS mice. Restraining OXPHOS generates a ROS‐mediated rewiring of lipid metabolism through enhanced BCAA catabolism and lipid synthesis. Skm and WAT perturbations in lipid species are observed, defining a Low_OXPHOS phenotype of adiposity and lipotoxicity. Edaravone treatment restores normal ROS and lipid metabolism, reducing v‐WAT deposits and preventing the setting of IR mediated by mitochondrial dysfunction.